JAK inhibitors did not increase the risk of major adverse cardiovascular events in patients with rheumatoid arthritis within the first two years of treatment: comment on the article by Aymon et al

Disclosureform Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.